相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment
Joon Ho Moon et al.
ANNALS OF HEMATOLOGY (2010)
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Lanlan Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study
Kathy Chun et al.
LEUKEMIA RESEARCH (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Tamer E. Fandy et al.
BLOOD (2009)
Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities
Farhad Ravandi et al.
CANCER (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
Matilde Y. Follo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
Sabine Knipp et al.
LEUKEMIA RESEARCH (2008)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
K. Raj et al.
LEUKEMIA (2007)
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
Masamitsu Yanada et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
Bjoern Rueter et al.
BLOOD (2007)
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
Hagop M. Kantarjian et al.
CANCER (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
An epigenetic approach to the treatment of advanced MDS;: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
PW Wijermans et al.
ANNALS OF HEMATOLOGY (2005)
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia:: review of cytogenetic and molecular studies
B Hackanson et al.
ANNALS OF HEMATOLOGY (2005)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
L Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine
M Lübbert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
